Golax: Uses, Dosage & Side Effects

What Is Golax and What Is It Used For?

Golax contains the active substance macrogol 4000, a high-molecular-weight polymer of ethylene oxide with an average molecular weight of approximately 4,000 daltons. Macrogol 4000, also widely known as polyethylene glycol 4000 (PEG 4000), belongs to the pharmacological class of osmotic laxatives (ATC code A06AD15). It is one of the most extensively studied and widely prescribed laxatives globally, and is recommended as a first-line treatment for constipation by leading international gastroenterology organizations including the World Gastroenterology Organisation (WGO), the American Gastroenterological Association (AGA), and the National Institute for Health and Care Excellence (NICE).

The mechanism of action of macrogol 4000 is based on simple physical chemistry rather than pharmacological activity. When dissolved in water and ingested, macrogol 4000 passes through the gastrointestinal tract essentially unchanged. Its large polymer chains form hydrogen bonds with surrounding water molecules, effectively holding water within the intestinal lumen. This osmotic action increases the water content and volume of the faecal mass, which has two important consequences: first, the stool becomes softer and more hydrated, making it easier to pass; and second, the increased luminal volume stimulates colonic motility through physiological stretch reflexes, promoting natural peristalsis and bowel evacuation.

One of the key pharmacological advantages of macrogol 4000 is that it is not absorbed from the gastrointestinal tract. The polymer is too large to cross the intestinal mucosa, and it does not undergo enzymatic degradation or metabolic transformation within the body. This means that macrogol 4000 has essentially no systemic pharmacological effects, no known pharmacokinetic interactions mediated by hepatic enzymes, and a very low potential for systemic side effects. The compound is excreted unchanged in the faeces. This purely local, physical mode of action distinguishes macrogol 4000 from stimulant laxatives (such as bisacodyl or senna) that act by directly stimulating nerve endings in the colonic mucosa and can lead to electrolyte disturbances, cramping, and potentially dependence with long-term use.

Golax is indicated for the symptomatic treatment of constipation in adults and children. Constipation is one of the most common gastrointestinal complaints worldwide, affecting an estimated 10 to 15 percent of the global population. The World Gastroenterology Organisation defines functional constipation using the Rome IV criteria, which include symptoms such as infrequent bowel movements (fewer than three per week), hard or lumpy stools, straining during defecation, a sensation of incomplete evacuation, and the need for manual maneuvers to facilitate bowel movements. Constipation can significantly impair quality of life, with many patients reporting reduced physical and social functioning comparable to other chronic conditions such as diabetes and depression.

The evidence base supporting macrogol (PEG) laxatives for the treatment of constipation is robust and high-quality. A Cochrane systematic review evaluating osmotic and stimulant laxatives for functional constipation concluded that macrogol-based preparations were significantly more effective than placebo in improving stool frequency, stool consistency, and overall symptoms. Comparative studies have also demonstrated that macrogol is at least as effective as, and in some outcomes superior to, lactulose (another commonly used osmotic laxative), with fewer reports of adverse gastrointestinal effects such as bloating and flatulence. These findings have informed the recommendations of major clinical practice guidelines, which consistently position macrogol as the preferred first-line osmotic laxative for both adults and children with functional constipation.

What Should You Know Before Taking Golax?

Contraindications

Golax must not be used in the following situations, as its use could be harmful or dangerous:

• Intestinal obstruction (ileus): Macrogol increases faecal volume through water retention. In a patient with a mechanical obstruction of the bowel, this increase in volume could worsen the obstruction, lead to bowel distension, and potentially cause perforation. Any known or suspected bowel obstruction is an absolute contraindication.
• Intestinal perforation: If the integrity of the intestinal wall is compromised, the introduction of additional fluid into the bowel lumen could cause leakage of intestinal contents into the peritoneal cavity, leading to peritonitis, which is a life-threatening emergency.
• Severe inflammatory bowel disease: In patients with severe active inflammatory bowel disease (such as ulcerative colitis or Crohn's disease), particularly when complicated by toxic megacolon, the use of osmotic laxatives is contraindicated as it may exacerbate bowel dilatation and increase the risk of perforation.
• Hypersensitivity: Do not use Golax if you are allergic to macrogol (polyethylene glycol) or any of the other ingredients in the formulation. Although allergic reactions to macrogol are rare, they have been reported and can include skin rashes, urticaria, and in very rare cases, anaphylaxis.

Warnings and Precautions

Before using Golax, discuss the following situations with your healthcare provider:

• Electrolyte imbalances: While Golax without electrolyte supplementation is not typically associated with significant electrolyte disturbances at standard doses, prolonged use or use at higher doses (particularly in elderly patients or those with renal impairment) may theoretically lead to changes in fluid and electrolyte balance. Patients with pre-existing electrolyte abnormalities should have their levels monitored during treatment.
• Renal impairment: Although macrogol 4000 is not absorbed systemically and is not cleared by the kidneys, patients with severe renal impairment may be more susceptible to fluid and electrolyte shifts caused by the osmotic action of the drug within the bowel. These patients should use Golax under medical supervision, and the lowest effective dose should be employed.
• Cardiac disease: Patients with heart failure or other conditions sensitive to fluid shifts should use macrogol-based laxatives with caution. While the amount of water retained in the bowel is relatively modest at standard doses, elderly patients or those with compromised cardiac function may be more sensitive to changes in fluid distribution.
• Aspiration risk: Patients with swallowing difficulties (dysphagia) or an impaired gag reflex should take Golax dissolved in water under supervision, as there is a risk of aspiration. Cases of aspiration pneumonia have been reported with polyethylene glycol-based bowel preparations administered via nasogastric tube.
• Duration of use: Golax is intended for short-term symptomatic relief of constipation. Treatment should normally not exceed 14 days without medical consultation. Persistent constipation may be a symptom of an underlying organic disorder (such as colorectal malignancy, hypothyroidism, or neurological conditions) that requires further investigation.

Pregnancy and Breastfeeding

Constipation is extremely common during pregnancy, affecting approximately 25 to 40 percent of pregnant women, primarily due to hormonal changes (elevated progesterone levels relaxing smooth muscle tone in the bowel), the physical pressure of the enlarging uterus on the colon, reduced physical activity, and iron supplementation. Macrogol 4000 is generally considered an appropriate choice for managing constipation during pregnancy because it is not absorbed from the gastrointestinal tract and therefore has no systemic exposure that could affect the developing fetus.

Large observational studies and post-marketing surveillance data have not identified an increased risk of malformations or adverse fetal or neonatal outcomes associated with the use of macrogol-based laxatives during pregnancy. The British National Formulary (BNF) classifies macrogol as a laxative that can be used in pregnancy when non-pharmacological measures (such as increased fluid and fiber intake) are insufficient. However, as with any medication during pregnancy, Golax should be used only when necessary and preferably after consultation with a healthcare provider.

Macrogol 4000 is not absorbed into the systemic circulation and therefore is not expected to be present in breast milk. It is considered compatible with breastfeeding. No specific precautions are needed for breastfeeding mothers using Golax at standard doses.

Use in Children

Functional constipation is one of the most common gastrointestinal complaints in childhood, accounting for approximately 3 to 5 percent of all pediatric outpatient visits. Macrogol-based laxatives are recommended as first-line pharmacological treatment for functional constipation in children by both the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), as well as by NICE. Studies in children have demonstrated that macrogol is more effective than lactulose and is well tolerated with minimal side effects. The dose for children should always be determined by a healthcare provider based on the child's age, weight, and clinical situation.

How Does Golax Interact with Other Drugs?

Because macrogol 4000 is not absorbed from the gastrointestinal tract and does not undergo hepatic metabolism, it has no known systemic pharmacokinetic drug interactions. It does not inhibit or induce cytochrome P450 enzymes, it does not bind to plasma proteins, and it does not compete with other drugs for renal elimination. This makes macrogol 4000 one of the safest laxatives from a drug interaction perspective, particularly for elderly patients and those on multiple medications (polypharmacy).

However, there is an important practical consideration regarding the absorption of concomitantly administered oral medications. By increasing the water content and transit rate of intestinal contents, osmotic laxatives like macrogol 4000 may theoretically reduce the time available for other orally administered drugs to be absorbed from the gastrointestinal tract. This is a class effect shared by all osmotic and stimulant laxatives, and its clinical significance depends on the pharmacokinetic properties of the co-administered drug.

Medications with a narrow therapeutic index or those requiring consistent absorption for clinical efficacy are of particular concern. These include:

As a general precaution, it is advisable to take other oral medications at least 2 hours before or after taking Golax. This timing gap allows the co-administered medication to be absorbed before the osmotic laxative effect alters intestinal transit. If you are taking any medications listed above or other drugs with a narrow therapeutic window, discuss the optimal timing schedule with your doctor or pharmacist.

It is worth noting that this interaction is theoretical and based on pharmacological reasoning rather than specific clinical studies demonstrating reduced drug efficacy when co-administered with macrogol 4000 at standard doses. At the recommended dose of 4 g, the effect on intestinal transit is relatively mild compared to the high-dose macrogol preparations used for bowel preparation before colonoscopy (which use doses of 60 to 240 g). Nevertheless, the precautionary timing recommendation is endorsed by regulatory agencies and product information documents as a standard safety measure.

What Is the Correct Dosage of Golax?

Golax should always be used according to your doctor's or pharmacist's instructions. Each sachet contains 4 g of macrogol 4000, which should be dissolved in approximately 50 to 100 mL of water (about half a glass) before ingestion. The powder dissolves readily in water at room temperature. Stir until dissolved and drink the solution. Golax can be taken with or without food, although taking it on an empty stomach may result in a faster onset of action.

Adults

The onset of the laxative effect typically occurs within 24 to 48 hours of the first dose. In some cases, particularly in patients with more severe or prolonged constipation, it may take 2 to 3 days of regular use to establish a comfortable bowel pattern. Do not exceed the recommended dose in an attempt to achieve a faster effect.

Children

Macrogol 4000 can be used in children for the treatment of functional constipation, and is endorsed for this purpose by ESPGHAN, NASPGHAN, and NICE. The dose for children is lower than for adults and depends on the child's age and weight. It is essential that the pediatric dose is determined and supervised by a healthcare provider. In general, children aged 2 to 7 years may be started on 1 sachet (4 g) once daily, while older children (8 to 17 years) may receive 1 to 2 sachets daily, titrated to clinical effect. For children under 2 years of age, the use of macrogol-based laxatives should be directed by a pediatric specialist.

Elderly Patients

No specific dose adjustment is required for elderly patients. However, older adults are more susceptible to dehydration and electrolyte imbalances, and they may have co-morbidities (such as renal impairment or heart failure) that necessitate careful monitoring. It is generally advisable to start with the lowest effective dose (1 sachet daily) and titrate upward as needed. Adequate fluid intake should be maintained during treatment, and elderly patients should be encouraged to drink sufficient water throughout the day.

Missed Dose

If you forget to take a dose of Golax, simply take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed dose. Missing a single dose is unlikely to cause problems, as macrogol 4000 does not build up in the body and its effects are purely local within the intestine.

Overdose

Taking more Golax than recommended may cause diarrhea, abdominal cramps, and excessive fluid loss. Severe diarrhea caused by an overdose of osmotic laxatives can lead to dehydration and electrolyte disturbances, particularly in vulnerable populations such as young children, elderly patients, and those with renal or cardiac disease. If significant overdose occurs, stop taking the product, maintain adequate fluid intake, and seek medical advice. In most cases, symptoms will resolve once the excess macrogol has been eliminated from the bowel. There is no specific antidote; treatment is supportive, with attention to fluid and electrolyte replacement if clinically indicated.

How to Prepare and Take Golax

1. Open the sachet: Tear the sachet along the dotted line.
2. Pour into water: Empty the entire contents of the sachet into a glass containing approximately 50 to 100 mL of water (about half a standard glass).
3. Stir: Stir the mixture until the powder is completely dissolved. The solution should be clear.
4. Drink: Drink the solution promptly. You may follow with additional water if desired.
5. Timing: Golax can be taken at any time of day, with or without food. For most patients, taking it in the morning or evening is convenient. Maintain consistent timing for best results.

What Are the Side Effects of Golax?

Like all medicines, Golax can cause side effects, although not everybody gets them. Macrogol 4000 has a well-established safety profile, supported by decades of clinical use and extensive post-marketing surveillance data. Because macrogol 4000 is not absorbed from the gastrointestinal tract, the side effects are predominantly limited to the gastrointestinal system and are generally mild and self-limiting.

The following side effects have been reported with macrogol 4000 and macrogol-based laxatives. The frequencies are classified according to the internationally recognized convention used in drug safety reporting:

The most commonly reported side effects are gastrointestinal in nature and are typically related to the laxative mechanism of action. Abdominal discomfort, bloating, and diarrhea usually occur when the dose is higher than needed for the individual patient and can often be managed by reducing the dose. If diarrhea occurs, the dose should be reduced or treatment temporarily suspended until symptoms resolve, and then restarted at a lower dose.

Allergic reactions to macrogol (polyethylene glycol) are rare but have been reported in the literature and post-marketing surveillance. PEG is a widely used excipient in pharmaceuticals, cosmetics, and food products, and sensitization can occur through multiple routes of exposure. Patients with a known allergy to polyethylene glycol should not use Golax. Cross-reactivity with polysorbates (another PEG-containing compound used as an excipient) has been reported in some cases.

There have been very rare post-marketing reports of serious allergic reactions including anaphylaxis associated with macrogol-containing products. If you experience symptoms such as difficulty breathing, swelling of the face, lips, tongue or throat, or a severe skin rash after taking Golax, stop taking the product immediately and seek urgent medical attention.

How Should You Store Golax?

Proper storage of medications is important to ensure their continued efficacy and safety throughout their shelf life. Golax powder for oral solution in sachets should be stored according to the following guidelines:

• Temperature: Store below 25°C (77°F). Do not freeze. There is no requirement for refrigeration.
• Moisture: Keep sachets in their original packaging until use. The powder is hygroscopic (it absorbs moisture from the air), so opened sachets should be used immediately. Do not store partially used sachets.
• Light: Protect from direct sunlight. Store in the original outer carton when not in use.
• Children: Keep all medicines out of the sight and reach of children.
• Expiry date: Do not use Golax after the expiry date stated on the sachet and outer carton. The expiry date refers to the last day of that month.

Once the powder has been dissolved in water, the solution should be consumed immediately. Do not prepare the solution in advance and store it, as there are no stability data for the reconstituted product. If you do not drink the prepared solution within a short time (approximately 30 minutes), discard it and prepare a fresh dose.

Do not dispose of unused medicines in household waste or via wastewater. Ask your pharmacist about the proper method for disposing of medicines you no longer need. These measures help to protect the environment.

What Does Golax Contain?

The active substance in Golax is macrogol 4000 (also referred to as polyethylene glycol 4000 or PEG 4000). Each sachet contains 4 grams of macrogol 4000. Macrogol 4000 is a linear polymer of ethylene oxide with an average molecular weight of approximately 4,000 daltons. It is a white, waxy, free-flowing powder that is highly soluble in water and is chemically inert within the gastrointestinal tract.

Macrogol 4000 is produced through the controlled polymerization of ethylene oxide, resulting in a compound with the general formula H(OCH₂CH₂)_nOH, where n is approximately 90 for the 4000-dalton variant. The compound meets the specifications outlined in the European Pharmacopoeia and is manufactured under Good Manufacturing Practice (GMP) conditions.

Unlike some macrogol preparations intended for bowel preparation before colonoscopy or surgery, Golax does not contain added electrolytes (such as sodium chloride, sodium bicarbonate, or potassium chloride). The absence of electrolytes makes it suitable for standard constipation management but means it should not be used interchangeably with electrolyte-containing formulations designed for complete bowel lavage.

The powder is white to off-white in appearance and dissolves completely in water to form a clear, colorless, and tasteless or nearly tasteless solution. This neutral taste profile generally contributes to good patient acceptance and adherence, particularly compared to some other laxative preparations (such as lactulose or magnesium-containing products) that may have a sweet or unpleasant taste.